PH27052A - Biologically active molecules - Google Patents

Biologically active molecules Download PDF

Info

Publication number
PH27052A
PH27052A PH34991A PH34991A PH27052A PH 27052 A PH27052 A PH 27052A PH 34991 A PH34991 A PH 34991A PH 34991 A PH34991 A PH 34991A PH 27052 A PH27052 A PH 27052A
Authority
PH
Philippines
Prior art keywords
alkyl
aryl
chy
substituted
methyl
Prior art date
Application number
PH34991A
Other languages
English (en)
Inventor
Karnail Singh Atwal
George Charles Rovnyak
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/008,037 external-priority patent/US4855301A/en
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of PH27052A publication Critical patent/PH27052A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH34991A 1986-03-14 1987-03-06 Biologically active molecules PH27052A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83976786A 1986-03-14 1986-03-14
US91734986A 1986-10-09 1986-10-09
US07/008,037 US4855301A (en) 1986-10-09 1987-02-09 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters

Publications (1)

Publication Number Publication Date
PH27052A true PH27052A (en) 1993-02-01

Family

ID=27358497

Family Applications (1)

Application Number Title Priority Date Filing Date
PH34991A PH27052A (en) 1986-03-14 1987-03-06 Biologically active molecules

Country Status (17)

Country Link
EP (1) EP0237347B1 (pl)
JP (1) JPH0819113B2 (pl)
KR (1) KR900005014B1 (pl)
CA (1) CA1337655C (pl)
DE (1) DE3770661D1 (pl)
DK (1) DK169031B1 (pl)
ES (1) ES2039234T3 (pl)
FI (1) FI96683C (pl)
GR (1) GR3002715T3 (pl)
HU (1) HU206091B (pl)
IE (1) IE60114B1 (pl)
IL (1) IL81800A0 (pl)
NO (1) NO871044L (pl)
PH (1) PH27052A (pl)
PL (1) PL153727B1 (pl)
PT (1) PT84479B (pl)
SU (1) SU1713437A3 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62267272A (ja) * 1986-05-15 1987-11-19 Sanwa Kagaku Kenkyusho Co Ltd 新規なジヒドロピリミジン化合物及びその塩、これらの製法並びに該化合物を有効成分とする循環器系作用剤
US4847379A (en) * 1987-11-30 1989-07-11 E. R. Squibb & Sons, Inc. 3,6-dihydro-1,5(2H)-pyrimidinecarboxylic acid esters
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
MX9703518A (es) 1994-11-16 1997-08-30 Synaptic Pharma Corp Dihidropirimidinas y usos de las mismas.
EP0866708A4 (en) * 1995-11-16 1999-05-06 Synaptic Pharma Corp DIHYDROPIRIMIDINES AND THEIR USES
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
JP2002514199A (ja) * 1997-02-04 2002-05-14 ブリストル−マイヤーズ スクイブ カンパニー Npy拮抗剤としてのジヒドロピリミドン誘導体
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
WO2000078730A1 (en) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
JP4897217B2 (ja) * 2002-09-12 2012-03-14 ダイアクロン ファーマシューティカルズ インコーポレイテッド カルシウムチャンネル遮断薬
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214778A (ja) * 1984-03-08 1985-10-28 Suntory Ltd Ν置換3,4−ジヒドロピリミジン誘導体ならびにその製造法および用途
HUT42077A (en) * 1985-06-03 1987-06-29 Squibb & Sons Inc Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters
US4675321A (en) * 1986-02-07 1987-06-23 Merck & Co., Inc. Substituted pyrimidines useful as calcium channel blockers
CA1275410C (en) * 1986-03-14 1990-10-23 Karnail S. Atwal 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo) -3-substituted-2-thioxo(or oxo)-5- pyrimidinecarboxylic acids and esters

Also Published As

Publication number Publication date
EP0237347A2 (en) 1987-09-16
EP0237347B1 (en) 1991-06-12
FI871087A7 (fi) 1987-09-15
FI96683C (fi) 1996-08-12
HUT43832A (en) 1987-12-28
EP0237347A3 (en) 1988-11-02
FI96683B (fi) 1996-04-30
JPS62265271A (ja) 1987-11-18
PT84479B (pt) 1990-08-31
KR870008856A (ko) 1987-10-21
CA1337655C (en) 1995-11-28
SU1713437A3 (ru) 1992-02-15
NO871044D0 (no) 1987-03-13
DK131887A (da) 1987-09-15
DE3770661D1 (de) 1991-07-18
PL264629A1 (en) 1988-07-21
FI871087A0 (fi) 1987-03-12
PT84479A (en) 1987-04-01
NO871044L (no) 1987-09-15
IE60114B1 (en) 1994-06-01
JPH0819113B2 (ja) 1996-02-28
KR900005014B1 (ko) 1990-07-16
HU206091B (en) 1992-08-28
IE870633L (en) 1987-09-14
ES2039234T3 (es) 1993-09-16
GR3002715T3 (en) 1993-01-25
IL81800A0 (en) 1987-10-20
PL153727B1 (en) 1991-05-31
DK169031B1 (da) 1994-08-01
DK131887D0 (da) 1987-03-13

Similar Documents

Publication Publication Date Title
US4855301A (en) 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters
US4684656A (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl-3-(substituted sulfonyl)-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters and method of using them to lower blood pressure
US5202330A (en) 2-thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid diesters and 3-acyl-5-pyrimidinecarboxylic acids and esters
PH27052A (en) Biologically active molecules
US5470975A (en) Dihydropyrimidine derivatives
AU592569B2 (en) 2-thio or oxo-4-aryl or heterocyclo-1,5 (2h)- pyrimidinedi-carboxylic acid diesters and 3-acyl-5- pyrimidinecarboxylic acids and esters
EP0565546B1 (en) (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile
KR101629356B1 (ko) 퀴나졸리논 유도체의 제조방법
US4435401A (en) 4-Amino-6,7-dimethoxy-2-(4-heteroaryl-piperazino)quinazoline antihypertensives
US4689414A (en) 2-(substituted imino)-6-aryl-3,6-dihydro-4-substituted-1,5(2H)-pyrimidinecarboxylic acids and analogs
EP0236902B1 (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-substituted-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters
WO2012092442A1 (en) Therapeutic compounds and compositions
US4847379A (en) 3,6-dihydro-1,5(2H)-pyrimidinecarboxylic acid esters
JP2005513020A (ja) 新規化合物
JPS62240668A (ja) 1,2,3,4−テトラヒドロ−6−置換−4−アリ−ル(またはヘテロシクロ)−3−置換−2−チオキソ(またはオキソ)−5−ピリミジンカルボン酸類およびエステル類
US5234923A (en) Substitute indole and benzimidazole derivatives
EP0202654A2 (en) 5-Carboxy-1,4-dihydropyrimidine derivatives
US4753946A (en) Pyrimidinecarboxylic acid derivatives
US4883872A (en) 3-oxo-1,2,4-triazolo(4,3-A) pyrimidine-6-carboxylic acid esters
AU598238B2 (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3- {(substituted amino)carbonyl}-2-thioxo(or oxo)-5-pyrimidine -carboxylic acids and esters
US4668683A (en) Cardiotonic quinazoline derivatives
US6630506B1 (en) Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
WO1989006535A1 (en) 2-OXO-1-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXYLIC ACID ESTERS
JPS62155267A (ja) チアゾリジン誘導体
DD255339A5 (de) Verfahren zur herstellung von 5-byrimidincarbonsaeure-verbindungen